164 related articles for article (PubMed ID: 37045879)
1. Factors hindering coverage of targeted mass treatment with primaquine in a malarious township of northern Myanmar in 2019-2020.
Aung PL; Soe MT; Soe TN; Oo TL; Win KM; Cui L; Kyaw MP; Sattabongkot J; Okanurak K; Parker DM
Sci Rep; 2023 Apr; 13(1):5963. PubMed ID: 37045879
[TBL] [Abstract][Full Text] [Related]
2. The acceptability of targeted mass treatment with primaquine for local elimination of vivax malaria in a northern Myanmar township: a mixed-methods study.
Aung PL; Soe MT; Soe TN; Oo TL; Aung PP; Khin A; Thi A; Phuanukoonnon S; Okanurak K; Cui L; Kyaw MP; Parker DM
Parasit Vectors; 2021 Oct; 14(1):549. PubMed ID: 34689796
[TBL] [Abstract][Full Text] [Related]
3. Interventions for promoting patients' adherence to 14-day primaquine treatment in a highly malaria-endemic township in Myanmar: a qualitative study among key stakeholders.
Win KM; Aung PL; Ring Z; Linn NYY; Kyaw MP; Nguitragool W; Cui L; Sattabongkot J; Lawpoolsri S
Malar J; 2023 Oct; 22(1):302. PubMed ID: 37814267
[TBL] [Abstract][Full Text] [Related]
4. Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis.
Devine A; Parmiter M; Chu CS; Bancone G; Nosten F; Price RN; Lubell Y; Yeung S
PLoS Negl Trop Dis; 2017 May; 11(5):e0005602. PubMed ID: 28542194
[TBL] [Abstract][Full Text] [Related]
5. Community acceptability, participation, and adherence to mass drug administration with primaquine for Plasmodium vivax elimination in Southern Thailand: a mixed methods approach.
Saita S; Roobsoong W; Khammaneechan P; Sukchan P; Lawpoolsri S; Sattabongkot J; Cui L; Okanurak K; Phuanukoonnon S; Parker DM
Malar J; 2023 Jan; 22(1):17. PubMed ID: 36635642
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of G6PD deficiency and submicroscopic malaria parasites carriage in malaria hotspot area in Northwest, Tanzania.
Manjurano A; Lyimo E; Kishamawe C; Omolo J; Mosha J; Donald M; Kazyoba P; Kapiga S; Changalucha J
Malar J; 2023 Dec; 22(1):372. PubMed ID: 38062464
[TBL] [Abstract][Full Text] [Related]
7. Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.
Devine A; Battle KE; Meagher N; Howes RE; Dini S; Gething PW; Simpson JA; Price RN; Lubell Y
PLoS Med; 2021 Jun; 18(6):e1003614. PubMed ID: 34061843
[TBL] [Abstract][Full Text] [Related]
8. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
Milligan R; Daher A; Villanueva G; Bergman H; Graves PM
Cochrane Database Syst Rev; 2020 Aug; 8():CD012656. PubMed ID: 32816320
[TBL] [Abstract][Full Text] [Related]
9. The use of primaquine in malaria infected patients with red cell glucose-6-phosphate dehydrogenase (G6PD) deficiency in Myanmar.
Myat-Phone-Kyaw ; Myint-Oo ; Aung-Naing ; Aye-Lwin-Htwe
Southeast Asian J Trop Med Public Health; 1994 Dec; 25(4):710-3. PubMed ID: 7667719
[TBL] [Abstract][Full Text] [Related]
10. Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials.
Phommasone K; van Leth F; Peto TJ; Landier J; Nguyen TN; Tripura R; Pongvongsa T; Lwin KM; Kajeechiwa L; Thwin MM; Parker DM; Wiladphaingern J; Nosten S; Proux S; Nguon C; Davoeung C; Rekol H; Adhikari B; Promnarate C; Chotivanich K; Hanboonkunupakarn B; Jittmala P; Cheah PY; Dhorda M; Imwong M; Mukaka M; Peerawaranun P; Pukrittayakamee S; Newton PN; Thwaites GE; Day NPJ; Mayxay M; Hien TT; Nosten FH; Cobelens F; Dondorp AM; White NJ; von Seidlein L
PLoS One; 2020; 15(2):e0228190. PubMed ID: 32023293
[TBL] [Abstract][Full Text] [Related]
11. The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia.
Thriemer K; Poespoprodjo JR; Kenangalem E; Douglas NM; Sugiarto P; Anstey NM; Simpson JA; Price RN
PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008838. PubMed ID: 33175835
[TBL] [Abstract][Full Text] [Related]
12. G6PD deficiency alleles in a malaria-endemic region in the Western Brazilian Amazon.
Dombrowski JG; Souza RM; Curry J; Hinton L; Silva NRM; Grignard L; Gonçalves LA; Gomes AR; Epiphanio S; Drakeley C; Huggett J; Clark TG; Campino S; Marinho CRF
Malar J; 2017 Jun; 16(1):253. PubMed ID: 28619120
[TBL] [Abstract][Full Text] [Related]
13. Validation of G6PD Point-of-Care Tests among Healthy Volunteers in Yangon, Myanmar.
Oo NN; Bancone G; Maw LZ; Chowwiwat N; Bansil P; Domingo GJ; Htun MM; Thant KZ; Htut Y; Nosten F
PLoS One; 2016; 11(4):e0152304. PubMed ID: 27035821
[TBL] [Abstract][Full Text] [Related]
14. Chloroquine-Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial.
Awab GR; Imwong M; Bancone G; Jeeyapant A; Day NPJ; White NJ; Woodrow CJ
Am J Trop Med Hyg; 2017 Dec; 97(6):1782-1787. PubMed ID: 29141719
[TBL] [Abstract][Full Text] [Related]
15. G6PD deficiency at Sumba in Eastern Indonesia is prevalent, diverse and severe: implications for primaquine therapy against relapsing Vivax malaria.
Satyagraha AW; Sadhewa A; Baramuli V; Elvira R; Ridenour C; Elyazar I; Noviyanti R; Coutrier FN; Harahap AR; Baird JK
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003602. PubMed ID: 25746733
[TBL] [Abstract][Full Text] [Related]
16. Single Low Dose Primaquine (0.25 mg/kg) Does Not Cause Clinically Significant Haemolysis in G6PD Deficient Subjects.
Bancone G; Chowwiwat N; Somsakchaicharoen R; Poodpanya L; Moo PK; Gornsawun G; Kajeechiwa L; Thwin MM; Rakthinthong S; Nosten S; Thinraow S; Nyo SN; Ling CL; Wiladphaingern J; Kiricharoen NL; Moore KA; White NJ; Nosten F
PLoS One; 2016; 11(3):e0151898. PubMed ID: 27010542
[TBL] [Abstract][Full Text] [Related]
17. Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria.
Milligan R; Daher A; Graves PM
Cochrane Database Syst Rev; 2019 Jul; 7(7):CD012656. PubMed ID: 31274189
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia.
Lo E; Zhong D; Raya B; Pestana K; Koepfli C; Lee MC; Yewhalaw D; Yan G
Malar J; 2019 Oct; 18(1):340. PubMed ID: 31590661
[TBL] [Abstract][Full Text] [Related]
19. Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.
Watson J; Taylor WRJ; Bancone G; Chu CS; Jittamala P; White NJ
PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006440. PubMed ID: 29677199
[TBL] [Abstract][Full Text] [Related]
20. G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients.
Avalos S; Mejia RE; Banegas E; Salinas C; Gutierrez L; Fajardo M; Galo S; Pinto A; Mejia A; Fontecha G
Malar J; 2018 Nov; 17(1):415. PubMed ID: 30409136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
